Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Accounts Payables (2016 - 2025)

Arrowhead Pharmaceuticals' Accounts Payables history spans 16 years, with the latest figure at $32.9 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 127.83% year-over-year to $32.9 million; the TTM value through Dec 2025 reached $32.9 million, up 127.83%, while the annual FY2025 figure was $17.7 million, 55.2% up from the prior year.
  • Accounts Payables reached $32.9 million in Q4 2025 per ARWR's latest filing, up from $17.7 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $35.9 million in Q3 2023 to a low of $796000.0 in Q4 2022.
  • Average Accounts Payables over 5 years is $13.1 million, with a median of $9.8 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: tumbled 80.43% in 2022, then surged 1150.56% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $4.1 million in 2021, then crashed by 80.43% to $796000.0 in 2022, then surged by 460.3% to $4.5 million in 2023, then surged by 224.15% to $14.5 million in 2024, then surged by 127.83% to $32.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Accounts Payables are $32.9 million (Q4 2025), $17.7 million (Q3 2025), and $33.0 million (Q2 2025).